Craig Leonardi

, United States


Presentations

Safety of Tildrakizumab in Patients With Preexisting Metabolic Syndrome: Long-Term Data From the Post Hoc Analysis of 2 Phase 3 Clinical Trials (reSURFACE 1 and reSURFACE 2) 09 October 2019 00:00 - 00:00

Abstracts

Safety of Tildrakizumab in Patients With Preexisting Metabolic Syndrome: Long-Term Data From the Post Hoc Analysis of 2 Phase 3 Clinical Trials (reSURFACE 1 and reSURFACE 2) Psoriasis More